Lars Hedbys

Born 1957. Chairman of the Board of Directors since 2020.

Independent in relation to the Company and its management but independent in relation to major shareholders..

Education and experience: M.Sc. Chemical Engineering, Chalmers University of Technology, PhD Department of Pure and Applied Biochemistry, Lund Institute of Technology, University of Lund. Lars has 30 years’ experience from leading positions in life science companies. A large part of his career has involved research and development at for example AstraZeneca but Lars also has a vast experience in founding, running and developing companies in life science.

Current assignments: Chairman of the board of Strominnate AB, board member of Asgard Therapeutics AB, Chosa Oncology AB (publ), Cell Invent AB and Xintela AB (publ). Partner at Ventac Partners.

Previous assignments (last five years): CEO of Idogen AB (publ), Acting CEO of Pharmiva AB (publ), Chairman of the board of IAmPatient AB, board member of Hamlet Pharma AB (publ), alternate board member of CanImGuide AB and Immodulate AB.

Lars Hedbys holds 9 709 B-shares and 8 427 TO3  via company.